Expression of thymidine phosphorylase and vascular endothelial cell growth factor in human head and neck squamous cell carcinoma and their different characteristics

Cancer

Volumn 85, Issue 4, 1999, Pages 960-969

  Fukuiwa, Tatsuya ^a   Takebayashi, Yuji ^a   Akiba, Suminori ^a   Matsuzaki, Tsutomu ^a   Hanamure, Yutaka ^a   Miyadera, Kazutaka ^b   Yamada, Yuji ^b   Akiyama, Shin Ichi ^c  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Head and neck squamous cell carcinoma; Immunostaining; Proliferating cell nuclear antigen; Thymidine phosphorylase; Vascular endothelial cell growth factor

Indexed keywords

CYCLINE; DNA; THYMIDINE PHOSPHORYLASE; VASCULOTROPIN;

ARTICLE; CELL PROLIFERATION; DNA SYNTHESIS; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; ENDOTHELIAL GROWTH FACTORS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHOKINES; MALE; MICROCIRCULATION; MIDDLE AGED; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROLIFERATING CELL NUCLEAR ANTIGEN; THYMIDINE PHOSPHORYLASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033557989     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990215)85:4<960::AID-CNCR26>3.0.CO;2-P     Document Type: Article

References (52)

1. Iltzsch MH, el Kouni MH, Cha S. Kinetic studies of thymidine phosphorylase from mouse liver. Biochemistry 1985;24: 6799-807.
2. Friedkin D, Roberts D. The enzymatic synthesis of nucleosides. J Biol Chem 1954;207:245-56.
3. Krenisky TA, Koszalka GW, Tuttle JV. Purine nucleoside synthesis, an efficient method employing nucleoside phosphorylases. Biochemistry 1981;20:3615-21.
4. Zimmerman M, Seidenberg J. Deoxyribosyl transfer. J Biol Chem 1964;230:2618-21.
5. Gallo RC, Perry S, Breitman TR. The enzymatic mechanisms for deoxythymidine synthesis in human leukocytes. I. Substrate inhibition by thymidine and activation by phosphate or arsenate. J Biol Chem 1967;242:5059-68.
6. Krenitsky TA. Pentosyl transfer mechanisms of the mammalian nucleoside phosphorylases. J Biol Chem 1968;243:2871-5.
7. Desgranges C, Razaka G, Rabaud H, Bricaud H. Catabolism of thymidine in human blood platelets: purification and properties of thymidine phosphorylase. Biochim Biophys Acta 1981;654:211-8.
8. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui, K, et al. Angiogenic factor [letter]. Nature 1992;356:668.
9. Sumizawa T, Furukawa T, Haraguchi M, Yoshimura A, Takeyasu A, Ishizawa M, et al. Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J Biochem (Tokyo) 1993;114:9-14.
10. Haraguchi M, Miyadera K, Uemura K, Sumizawa T, Furukawa T, Yamada K, et al. Angiogenic activity of enzymes [letter]. Nature 1994;368:198.
11. Ishikawa F, Miyazono K, Hellman U, Drexler M, Wernstedt C, Hagiwara K, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989;338:557-662.
12. Miyazono K, Okabe T, Urabe A, Takasu F, Heldin CH. Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem 1987;262:4098-103.
13. Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y, et al. Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 1995;55:1687-90.
14. Pauly JL, Schuller MG, Zelcer AA, Kriss TA, Gore SS, Germain MJ. Identification and comparative analysis of thymidine phosphorylase in the plasma of healthy subjects and cancer patients. J Natl Cancer Inst 1977;58:1587-90.
15. Pauly JL, Paolini NS, Ebarb RL, Germain MJ. Elevated thymidine phosphorylase activity in the plasma and ascitic fluids of tumor-bearing animals. Proc Soc Exp Biol Med 1978;157:262-7.
16. Yoshimura A, Kuwazuru Y, Furukawa T, Yoshida H, Yamada K, Akiyama S. Purification and tissue distribution of human thymidine phosphorylase: high expression in lymphocytes, reticulocytes and tumors. Biochem Biophys Acta 1990;1034: 107-13.
17. Takebayashi Y, Yamada K, Maruyama I, Fujii R, Akiyama S, Aikou T. The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinoma. Cancer Lett 1995;92:1-7.
18. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996;88: 1110-7.
19. Reynolds K, Farzaneh F, Collins WP, Campbell S, Bourne TH, Lawton F, et al. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J Natl Cancer Inst 1994;86:1234-8.
20. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer 1995;64:79-82.
21. Fox SB, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse RM, et al. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 1996;73:275-80.
22. Takebayashi Y, Yamda K, Miyadera K, Sumizawa T, Furukawa T, Kinoshita F, et al. The activity and expression of thymidine phosphorylase in human solid tumors. Eur J Cancer 1996;32:1227-32.
23. Takebayashi Y, Miyadera K, Akiyama S, Hokita S, Yamada K, Akiba S, et al. Expression of thymidine phosphorylase in human gastric carcinoma. Jpn J Cancer Res 1996;87:288-95.
24. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
25. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, et al. The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266:11947-54.
26. Plate KH, Breier G, Welch HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-8.
27. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma [see comment citation in MEDLINE]. J Clin Oncol 1994;12:454-66.
28. Ellis LM, Fidler IJ. Angiogenesis and breast cancer metastasis [see comment citation in MEDLINE]. Lancet 1995;346: 388-90.
29. Obermair A, Kurz C, Czewenka K, Thoma M, Kaider A, Wagner T, et al. Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on reccurence-free survival. Int J Cancer 1995;62:126-31.
30. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997;89:139-47.
31. Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J Biol Chemo 1996; 271:29483-8.
32. Celis JE, Celis A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci USA 1985;82:3262-6.
33. Morris GF, Mathews MB, Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem 1989;264: 13856-64.
34. Moore KS, Sullivan K, Tan EM, Prystowsky MB. Proliferating cell nuclear antigen/cyclin is an interleukin 2-responsive gene. J Biol Chem 1987;262:8447-50.
35. del Giglio A, O'Brien S, Ford R, Saya H, Manning J, Keating M, et al. Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia. Blood 1992; 79:2717-20.
36. Maeda K, Chung YS, Takatsuka S, Ogawa Y, Onoda N, Sawada T, et al. Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer 1995;72:319-23.
37. Maehara Y, Emi Y, Baba H, Adachi Y, Akazawa K, Ichiyoshi Y, et al. Recurrences and related characteristics of gastric cancer. Br J Cancer 1996;74:975-9.
38. Harper ME, Glynne JE, Goddard L, Wilson DW, Matenhelia SS, Conn IG, et al. Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. Prostate 1992;20:243-53.
39. Aaltomaa S, Lipponen P, Syrjanen K. Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer. Anticancer Res 1993;13:533-8.
40. Robbins BA, del la Vega D, Ogata K, Tan EM, Nakamura RM. Immunohistochemical detection of proliferating cell nuclear antigen in solid human malignancies. Arch Pathol Lab Med 1987;111:841-5.
41. Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990;162:285-94.
42. Shin DM, Voravud N, Ro JY, Lee JS, Hong WK, Hittelman WN. Sequential increases in proliferating cell nuclear antigen expression in head and neck tumorigenesis: a potential biomarker. J Natl Cancer Inst 1993;85:971-8.
43. Hermane KP, Sobin LH. TNM classification of malignant tumours Fourth, fully revised edition. Berlin: Springer, 1987.
44. Jass JR, Sobin LH. World Health Organization international histological classification of tumors: New York: Springer-Verlag, 1989.
45. Hsu SM, Raine L, Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 1981;75: 734-8.
46. Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter KC, et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol 1995;176: 183-90.
47. Zar JH. Biostatistical analysis. 3rd edition. New Jersey: Prentice Hall, 1996.
48. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
49. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis [see comment citation in MEDLINE]. Cell 1994;79:185-8.
50. O'Brien TS, Fox SB, Dickinson AJ, Turley H, Westwood M, Moghaddam A, et al. Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res 1996; 56:4799-804.
51. Takebayashi Y, Akiyama S, Tani A, Furukawa T, Miyadera K, Yamada Y, et al. Induction of thymidine phosphorylase by hypoxia and relationship between expression of thymidine phosphorylase and apoptosis. Proc Am Assoc Cancer Res 1997;38:48-9.
52. Toi M, Inada K, Hoshida S, Suzuki H, Kondo S, Tominaga T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1995;1:961-4.